Talphera, Inc. (TLPH) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Telferra First Quarter 2025 Financial Results Conference Call. This call is being webcast live via the events page of the investor sections of Telferra's website at www.telferra.com. You may listen to a replay of this webcast by going to the investor section of Telferra's website. I would now like to turn the call over to Raffia Sadorian, Telferra's Chief Financial Officer. Thank you for joining us on the call today. Today, we announced our first quarter 2025 financial results and associated business updates in a press release. With me today are Vince Angotti, our Chief Executive Officer, and Dr. Shaquille Aslam, Telfair's Chief Medical Officer. Before we begin, I want to remind listeners that during this call, we will likely make forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties regarding the operations and future results of Telfera. Please refer to our press release in addition to the company's periodic current and annual reports filed with the SEC for a discussion of the risks associated with such forward-looking statements. These documents can also be found on our website within the Investors section. I'll hand the call to Vince. Thanks, Rafi. Good afternoon, and thank you to everyone joining our call today. It's only been about six weeks since our last call, so we're going to keep our prepared remarks brief. We began 2025 with strong momentum with a focus on the execution of our NEFRO CRRT trial that resulted in the approval from the FDA on a significantly decreased study size, the removal of certain exclusion criteria, and the activation of additional high volume sites to accelerate enrollment. In addition, a pipe financing was also completed. As detailed...